Sugi Predict

Sugi Predict / Compounds / SCHEMBL2406313

SCHEMBL2406313

SCHEMBL2406313

O=C(O)c1cccc(-c2cc(Cl)ccc2O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.58
▸ RXRB P28702 1/20 0.58
▸ PTGER1 P34995 7/20 0.54
▸ CYP2C9 P11712 3/20 0.54
▸ KMO O15229 1/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ ERN1 O75460 1/20 0.51
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ MAP4K4 O95819 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ SERPINE1 P05121 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ USP2 O75604 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2408930 0.85 CA1 (0.56) RXRARXRBCA1CA2NPC1
Potassium Ion SCHEMBL29383367 0.84 PTGER1 (0.45) RXRARXRBPTGER1CYP2C9CA1
SCHEMBL29383897 0.84 PTGER1 (0.47) RXRARXRBPTGER1CYP2C9CA1
Lithium Ion SCHEMBL29383941 0.84 PTGER1 (0.45) RXRARXRBPTGER1CYP2C9CA1
SCHEMBL16574048 0.83 RXRA (0.57) RXRARXRBPTGER1CYP2C9KMO
SCHEMBL442436 0.82 SRD5A2 (0.62) RXRARXRBPTGER1CYP2C9KMO
SCHEMBL5094107 0.81 ALOX5 (0.62) CA1CA2MEN1LMNATP53
SCHEMBL4350191 0.81 CNR2 (0.52) RXRARXRBKMOCA1CA2
SCHEMBL4346801 0.81 KDM1A (0.53) RXRARXRBPTGER1KMOCA1
SCHEMBL5567627 0.81 RXRA (0.54) RXRARXRBPTGER1KMOCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 — — US claimed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 — — EP claimed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 — — EP claimed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 — — WO claimed
US-12435042-B2 Process for the preparation of key intermediates for the synthesis of Eltrombopag or salt thereof F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) 2025-10-07 — — US disclosed
US-20220298116-A1 PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF F.l.S. - FABBRICA ITALIANA SINTETICI S.P.A (IT) 2022-09-22 — — US disclosed
EP-3994126-A1 PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) 2022-05-11 — — EP disclosed
WO-2021001044-A1 PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2021-01-07 — — WO disclosed
WO-2021001044-A1 PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2021-01-07 — — WO disclosed
US-20150093356-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2015-04-02 — — US disclosed
WO-2013049605-A1 PROCESSES FOR THE PREPARATION OF AN INTERMEDIATE IN THE SYNTHESIS OF ELTROMBOPAG ASSIA CHEMICAL INDUSTRIES LTD. (IL) 2013-04-04 — — WO disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 — — US disclosed
US-7335649-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2008-02-26 — — US disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 — — EP disclosed
US-7332481-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2008-02-19 — — US disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 — — EP disclosed
US-20070179192-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2007-08-02 — — US disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 — — US disclosed
US-7160870-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-01-09 — — US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK RXRA 4434/4885RXRB 2974/4885PTGER1 636/4885
US-20070179192-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK RXRA 4434/4885RXRB 2974/4885PTGER1 636/4885
US-20150093356-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK RXRA 4434/4885RXRB 2974/4885PTGER1 636/4885
US-12435042-B2 Process for the preparation of key intermediates for the synthesis of Eltrombopag or salt thereof HABP2, F5, THPO RXRA 3185/4885RXRB 3068/4885PTGER1 576/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK RXRA 4434/4885RXRB 2974/4885PTGER1 636/4885
US-20220298116-A1 PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF HABP2, F5, THPO RXRA 3185/4885RXRB 3068/4885PTGER1 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.